Transcenta Holding Limited (06628.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 0.83

From 52W high−80.81%

Volume1.88M

Market capHKD 403.84M

P/E (TTM)—

P/S (TTM)12.2x

Div yield—

Key dataSep 18, 2026

Open

HKD 0.83

From 52W high

−80.81%

Volume

1.88M

Market cap

HKD 403.84M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.7x

P/E (TTM)

—

RSI (14)

48.9

MomentumView details →

1D Return

+17.47%

YTD Return

−54.01%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.7x

EV/Sales

16.9x

P/S (TTM)

12.2x

P/B (TTM)

0.6x

ProfitabilityView details →

Gross Margin

64.74%

Net Margin

−569.50%

EBITDA Margin

−363.26%

ROE (TTM)

−29.16%

ROA (TTM)

−18.09%

Asset Turnover

0.03x

GrowthView details →

Revenue YoY

+201.03%

EPS YoY

+40.94%

FCF YoY

+64.05%

Revenue CAGR 3Y

−58.58%

EPS CAGR 3Y

+33.33%

EBITDA YoY

+51.45%

MomentumView details →

1D Return

+17.47%

YTD Return

−54.01%

1Y Return

−78.62%

RSI (14)

48.9

vs 50D SMA

−7.10%

vs 200D SMA

−47.84%

Capital & dividendView details →

Debt/Equity

0.25x

Current Ratio

0.18x

Quick Ratio

0.12x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.19

EPS Surprise

64.48%

Beats (12Q)

1/12

Next Q EPS Est

−HKD 0.53

Avg Surprise (4Q)

64.48%

Rev Surprise

−6.84%

Financials snapshotView financials →

Revenue (TTM)

28.32M

Net Income (TTM)

−161.29M

Op. CF (TTM)

−59.97M

Next earningsMar 31, 2027 →

Latest newsMore news →

Pharmaceutical company Yaojie Ankang (02617.HK) reported interim results for the six months ended June 2026, with revenue of RMB 35.46 million and a narrowed net loss of RMB 95.47 million, compared with a loss of RMB 123 million in the same period last year.25d ago

Transcenta Holding announced the sale of its CDMO assets to WuXi Biologics for RMB 190 million, excluding intellectual property related to its candidate drug pipeline and core biomanufacturing platform.45d ago

Similar companies

ProKidney Corp.PROK ARS Pharmaceuticals, Inc.SPRY Larimar Therapeutics, Inc.LRMR Editas Medicine, Inc.EDIT Galectin Therapeutics Inc.GALT C4 Therapeutics, Inc.CCCC Find similar companies →

Latest newsMore news →

Pharmaceutical company Yaojie Ankang (02617.HK) reported interim results for the six months ended June 2026, with revenue of RMB 35.46 million and a narrowed net loss of RMB 95.47 million, compared with a loss of RMB 123 million in the same period last year.25d ago Transcenta Holding announced the sale of its CDMO assets to WuXi Biologics for RMB 190 million, excluding intellectual property related to its candidate drug pipeline and core biomanufacturing platform.45d ago